结直肠癌的治疗策略：多巴胺 D2 受体拮抗剂的抗肿瘤功效。

IF 1.6 4区医学 Q4 TOXICOLOGY Toxicological Research Pub Date : 2024-08-07 eCollection Date: 2024-10-01 DOI:10.1007/s43188-024-00259-8

Sang Hoon Joo, Kyung-Soo Chun

{"title":"结直肠癌的治疗策略：多巴胺 D2 受体拮抗剂的抗肿瘤功效。","authors":"Sang Hoon Joo, Kyung-Soo Chun","doi":"10.1007/s43188-024-00259-8","DOIUrl":null,"url":null,"abstract":"Colorectal cancer (CRC) is one of the leading causes of death, accounting for more than half a million deaths annually. Even worse, an increasing number of cancer cases are diagnosed yearly, and two and a half million new cancer cases are estimated to be diagnosed in 2035. Some antipsychotic drugs, especially those targeting dopamine receptor (DR) D2, demonstrated anticancer activity. Studies have revealed the potential of DRD2 antagonists as anticancer therapeutics, whether alone or as an adjuvant, in treating breast cancer, lung cancer, and others. Emerging evidences indicate DRD2 is involved in the CRC biology, and the association between DRD2 and CRC could be utilized in treating CRC. This study selected DRD2 antagonists with anticancer activity to elucidate the possibility of DRD2 antagonists as new therapeutics for treating CRC.","PeriodicalId":23181,"journal":{"name":"Toxicological Research","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11436607/pdf/","citationCount":"0","resultStr":"{\"title\":\"Therapeutic strategies for colorectal cancer: antitumor efficacy of dopamine D2 receptor antagonists.\",\"authors\":\"Sang Hoon Joo, Kyung-Soo Chun\",\"doi\":\"10.1007/s43188-024-00259-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Colorectal cancer (CRC) is one of the leading causes of death, accounting for more than half a million deaths annually. Even worse, an increasing number of cancer cases are diagnosed yearly, and two and a half million new cancer cases are estimated to be diagnosed in 2035. Some antipsychotic drugs, especially those targeting dopamine receptor (DR) D2, demonstrated anticancer activity. Studies have revealed the potential of DRD2 antagonists as anticancer therapeutics, whether alone or as an adjuvant, in treating breast cancer, lung cancer, and others. Emerging evidences indicate DRD2 is involved in the CRC biology, and the association between DRD2 and CRC could be utilized in treating CRC. This study selected DRD2 antagonists with anticancer activity to elucidate the possibility of DRD2 antagonists as new therapeutics for treating CRC.\",\"PeriodicalId\":23181,\"journal\":{\"name\":\"Toxicological Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11436607/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Toxicological Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s43188-024-00259-8\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"TOXICOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicological Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43188-024-00259-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"TOXICOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

结肠直肠癌（CRC）是导致死亡的主要原因之一，每年造成 50 多万人死亡。更糟糕的是，每年确诊的癌症病例越来越多，预计到 2035 年将新增 250 万例癌症病例。一些抗精神病药物，尤其是以多巴胺受体（DR）D2 为靶点的药物，显示出抗癌活性。研究揭示了 DRD2 拮抗剂作为抗癌疗法的潜力，无论是单独使用还是作为辅助药物，都能治疗乳腺癌、肺癌和其他癌症。新的证据表明，DRD2 参与了 CRC 的生物学过程，DRD2 与 CRC 的关联可用于治疗 CRC。本研究选择了具有抗癌活性的 DRD2 拮抗剂，以阐明 DRD2 拮抗剂作为治疗 CRC 的新疗法的可能性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Therapeutic strategies for colorectal cancer: antitumor efficacy of dopamine D2 receptor antagonists.

Colorectal cancer (CRC) is one of the leading causes of death, accounting for more than half a million deaths annually. Even worse, an increasing number of cancer cases are diagnosed yearly, and two and a half million new cancer cases are estimated to be diagnosed in 2035. Some antipsychotic drugs, especially those targeting dopamine receptor (DR) D2, demonstrated anticancer activity. Studies have revealed the potential of DRD2 antagonists as anticancer therapeutics, whether alone or as an adjuvant, in treating breast cancer, lung cancer, and others. Emerging evidences indicate DRD2 is involved in the CRC biology, and the association between DRD2 and CRC could be utilized in treating CRC. This study selected DRD2 antagonists with anticancer activity to elucidate the possibility of DRD2 antagonists as new therapeutics for treating CRC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Toxicological Research TOXICOLOGY-

CiteScore

4.20

自引率

4.30%

发文量

期刊介绍： Toxicological Research is the official journal of the Korean Society of Toxicology. The journal covers all areas of Toxicological Research of chemicals, drugs and environmental agents affecting human and animals, which in turn impact public health. The journal’s mission is to disseminate scientific and technical information on diverse areas of toxicological research. Contributions by toxicologists, molecular biologists, geneticists, biochemists, pharmacologists, clinical researchers and epidemiologists with a global view on public health through toxicological research are welcome. Emphasis will be given to articles providing an understanding of the toxicological mechanisms affecting animal, human and public health. In the case of research articles using natural extracts, detailed information with respect to the origin, extraction method, chemical profiles, and characterization of standard compounds to ensure the reproducible pharmacological activity should be provided.